Methods for the treatment of myopia
The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective α-2 adrenergic receptor agonist.
1. A method for treating myopia comprising administering a composition comprising from about 0.1% to about 1.75% w/v aceclidine to a subject in need thereof, wherein w/v denotes weight by total volume of the composition.
2. The method of claim 1 , wherein the composition further comprises one or more surfactants.
3. The method of claim 1 , wherein the one or more surfactants are selected from the group consisting of anionic surfactants and nonionic surfactants.
4. The method of claim 3 , wherein the one or more surfactants are nonionic surfactants.
5. The method of claim 4 , wherein the one or more nonionic surfactants are selected from the group consisting of a polysorbate, tyloxapol, a poloxamer, a cyclodextrin, vitamin E TPGS, a polyoxyl castor oil, a polyoxyl stearate, polyethylene glycol, a polyoxyethylene glycol alkyl ether and 2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol.
6. The method of claim 5 , wherein the one or more nonionic surfactants is a polysorbate.
7. The method of claim 6 , wherein the one or more nonionic surfactants is polysorbate 80.
8. The method of claim 1 , wherein the composition further comprises one or more viscosity agents.
9. The method of claim 8 , wherein the one or more viscosity agents are selected from the group consisting of a cellulose derivative, hyaluronate, a carbomer and a gum.
10. The method of claim 9 , wherein the one or more viscosity agents are cellulose derivatives.
11. The method of claim 10 , wherein the one or more viscosity agents is hydroxypropylmethyl cellulose.
12. The method of claim 1 , wherein the composition further comprises a polyol.
13. The method of claim 12 , wherein the polyol is selected from the group consisting of mannitol, glycerol, erythritol, lactitol, xylitol, sorbitol, isosorbide, ethylene glycol, propylene glycol, maltitol, threitol, arabitol and ribitol.
14. The method of claim 13 , wherein the polyol is mannitol.
15. The method of claim 1 , wherein the composition further comprises one or more selective α-2 adrenergic receptor agonists.
16. The method of claim 15 , wherein the one or more selective α-2 adrenergic receptor agonists is selected from the group consisting of brimonidine, guanfacine, fadolmidine, dexmedetomidine, (+)-(S)-4-[1-(2,3-dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione, 1-[(imidazolidin-2-yl)imino]indazole.
17. The method of claim 16 , wherein the one or more selective α-2 adrenergic receptor agonists is brimonidine.
18. The method of claim 1 , wherein myopia is ameliorated.
19. The method of claim 1 , wherein myopia is reduced.
20. A method for treating myopia comprising administering a composition comprising about 1.25% w/v aceclidine, about 0.01% w/v brimonidine, about 1.4% w/v carboxymethyl cellulose to a subject in need thereof, wherein the subject is older than 5 years of age and younger than 35 years of age and wherein w/v denotes weight by total volume of the composition.
21. The method of claim 20 , wherein the composition has a pH of about 5.75 and further comprises potassium sorbate and about 4 millimolar phosphate buffer.
22. The method of claim 20 , wherein the composition further comprises 0.0075% w/v cyclopentolate hydrochloride.
23. The method of claim 20 , wherein the subject does not experience an increase in accommodation.
24. A method for treating myopia comprising administering a composition comprising about 1.25% w/v aceclidine, about 0.010% w/v brimonidine, about 2.5% w/v polysorbate, about 1.45% w/v carboxymethyl cellulose, about 0.07% EDTA and about 0.01% w/v potassium sorbate to a subject in need thereof, wherein w/v denotes weight by total volume of the composition.